Unlock instant, AI-driven research and patent intelligence for your innovation.

Medicine composition for treating vaginal diseases

A composition and drug technology, applied in the direction of drug combination, disease, antibacterial drug, etc.

Inactive Publication Date: 2009-08-05
BEIJING JINCHENG TAIER PHARMA CO LTD
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] At present, there is no report or corresponding technical enlightenment on the combined use of nifuratel and tinidazole in the treatment of vaginal diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine composition for treating vaginal diseases
  • Medicine composition for treating vaginal diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] Example 1 - Formulation 1

[0017] After grinding 10g promestriene and 30g tinidazole evenly, mix them evenly, take an appropriate amount of acetone, put 10g promestriene and 30g tinidazole into acetone, make it completely dissolved for use, and make 1 solution; take another 20g Add 100 grams of water to 1 gram of hydroxypropyl β-cyclodextrin, grind it evenly, and make it into a paste, mix 1 solution with it, stir well, mix well, dry at 30°C, and then use ethanol to remove the unincluded Partially washed and dried at 40°C to obtain the clathrate, detect the content of the clathrate and the content of the organic solvent, so that the organic solvent meets the requirements of the limit, and then mix the well-mixed clathrate with water at 60-70°C The melted and slightly cooled semi-synthetic fatty acid is ground and mixed, and when the temperature is lowered to 40°C, it is poured into a suppository mold coated with paraffin oil, and the excess part is scraped off after coo...

Embodiment 2

[0018] Example 2 - Recipe 2

[0019] After grinding 10g promestriene and 20g tinidazole evenly, mix them evenly, take an appropriate amount of acetone, put 10g promestriene and 20g tinidazole into acetone, make it completely dissolved for use, and make 1 solution; take another 20g Add 100 grams of water to 1 gram of hydroxypropyl β-cyclodextrin, grind it evenly, and make it into a paste, mix 1 solution with it, stir well, mix well, dry at 30°C, and then use ethanol to remove the unincluded Partially washed and dried at 40°C to obtain the clathrate, detect the content of the clathrate and the content of the organic solvent, so that the organic solvent meets the requirements of the limit, and then mix the well-mixed clathrate with water at 60-70°C The melted and slightly cooled semi-synthetic fatty acid is ground and mixed, and when the temperature is lowered to 40°C, it is poured into a suppository mold coated with paraffin oil, and the excess part is scraped off after cooling ...

Embodiment 3

[0020] Example 3 - Recipe 3

[0021] After grinding 10g promestriene and 15g tinidazole evenly, mix them evenly, take an appropriate amount of acetone, put 10g promestriene and 15g tinidazole into acetone, make it completely dissolved for use, and make 1 solution; take another 25g Add 125 grams of water to 1 gram of hydroxypropyl β-cyclodextrin, grind it evenly, and make it into a paste, mix 1 solution with it and stir well, mix well, dry at 30°C, and then use ethanol to remove the unincluded Partially washed and dried at 40°C to obtain the clathrate, detect the content of the clathrate and the content of the organic solvent, so that the organic solvent meets the requirements of the limit, and then mix the well-mixed clathrate with water at 60-70°C Melted and slightly cooled semi-synthetic coconut oil is ground and mixed, and when the temperature is lowered to 40°C, it is poured into a suppository mold coated with paraffin oil, and after cooling, the excess part is scraped off...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
weightaaaaaaaaaa
Login to View More

Abstract

The invention relates to a pharmaceutical composition, in particular to a pharmaceutical composition for treating vaginal diseases, which contains promestriene and tinidazole as active ingredients, and the weight ratio of promestriene and tinidazole is 1:1 ~1:4, preferably 1:2~1:3, most preferably 1:3. The daily dose of promestriene is 6-10 mg, preferably 8-10 mg, most preferably 10 mg; the daily dose of tinidazole is 10-60 mg, preferably 20-40 mg, most preferably 30 mg. The pharmaceutical composition of the present invention can be prepared into dosage forms for intravaginal administration, such as suppositories, capsules, tablets, creams and the like.

Description

technical field [0001] The invention relates to a pharmaceutical composition, in particular to a pharmaceutical composition for treating vaginal diseases, which uses promestriene and tinidazole as active components. Background technique [0002] Gynecological vaginal diseases are common and frequently-occurring diseases in women, and trichomonal vaginitis and bacterial vaginosis are typical gynecological vaginal diseases. At present, the domestic drugs for the treatment of these two diseases are mainly drugs of tinidazole series. Tinidazole is a derivative of 5-nitroimidazole, which has no cytotoxicity itself, and produces an unstable reduced intermediate metabolite with a short half-life, which acts on the growth phase of anaerobic bacteria and can penetrate into the cells of bacteria , destroys DNA chains, inhibits DNA synthesis, and promotes bacterial death. It has inhibitory effects on protozoa such as Trichomonas vaginalis, Entamoeba histolytica and Giardia lamblia, an...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/565A61K9/02A61K9/06A61K9/20A61K9/48A61P15/02A61P31/04A61K31/4164
Inventor 杨军
Owner BEIJING JINCHENG TAIER PHARMA CO LTD